**Cost:**

Not specified.

**Outcomes:**

* Children with heterozygous familial hypercholesterolaemia (FH) should be managed by paediatric health professionals with expertise in FH.
* Statin to be considered by the age of 10 years and use age appropriate target LDL-C level in children with FH.
* Dietary and lifestyle advice should begin in early childhood.
* From the age of 14 years, consider joint review with adult lipidologist in transition clinic with transfer to adult lipid clinic at 16 to 18 years

**Project aims:**

This is a consensus statement by HEARTUK on a strategy with age appropriate guidance for managing children and young people with heterozygous FH in the UK. The existing NICE CG71 guideline does not address in detail the management of children with FH. We aim to do this here and suggest practical LDL-Cholesterol target concentrations. We have not included formal evidence grading of the recommendations since this is a position statement of UK paediatric FH expert opinion.

**Project title:**

Current management of children and young people with heterozygous familial hypercholesterolaemia- HEARTUK statement of care